ROVI released today its financial results for the first half of 2021. Below, we share some of the main indicators:
- Operating revenue increased by 52% to 290.1 million euros in the first half of 2021, driven by the strength of the toll manufacturing business, which grew by 172%, and the specialty pharmaceutical business, where sales rose 25%.
- Total revenue increased by 52% to 290.6 million euros in the first half of 2021.
- Sales of the heparin franchise (Low Molecular Weight Heparins (LMWH) and other heparins) increased by 26% to 131.4 million euros in the first half of 2021.
- Heparin sales represented 45% of operating revenue in the first half of 2021 compared to 54% in the first half of 2020.
- Sales of LMWH (Enoxaparin biosimilar and Bemiparin) increased by 27% to 127.8 million euros in the first half of 2021. Sales of the enoxaparin biosimilar increased 27% to 62.7 million euros in the first half of 2021 and sales of Bemiparin increased 26% to 65.1 million euros.
- EBITDA increased by 75%, from 42.4 million euros in the first half of 2020 to 74.0 million euros in the first half of 2021, reflecting a 3.3 percentage point rise in the EBITDA margin to 25.5% in the first half of 2021.
- Net profit increased by 72%, from 29.6 million euros in the first half of 2020 to 51.0 million euros in the first half of 2021.
- As a result of the expansion of the collaboration agreement with Moderna and the current visibility of ROVI’s business areas, the company has again upgraded its forecast for growth in operating revenue in 2021, raising it to between 35% and 40%